Additionally, the predictive differences of ALI in different regions, ethnicities, tumor types, subtypes of breast cancer (e.g., HER2+ vs triple-negative), and different treatment strategies should be studied to provide personalized clinical references. This evidence concerns the gene ERBB2 and neoplasm.